Wolters Kluwer Health Investor Seminar ALPHEN AAN DEN RIJN,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Wolters Kluwer Health Investor Seminar

ALPHEN AAN DEN RIJN, Netherlands, Oct. 28, 2013 (GLOBE NEWSWIRE) --

Alphen aan den Rijn (October 28, 2013) - Wolters Kluwer, a global leader in professional information services, will host a seminar today for analysts and institutional investors covering its Health division. The afternoon seminar will be chaired by Nancy McKinstry, CEO of Wolters Kluwer, with presentations by: * Bob Becker, CEO of Wolters Kluwer Health * Susan Driscoll, CEO of Professional & Education * Cathy Wolfe, CEO of Medical Research * Arvind Subramanian, CEO of Clinical Solutions * Dr. Denise Basow, General Manager of UpToDate The Health management team will present an in-depth view of the business and provide a perspective on customer needs, market trends, competition, and strategic priorities. No new trading information will be disclosed. The event, which takes place in London, will start at 14:00 BST (15:00 CET) and finish around 17:00 BST (18:00 CET). The presentations will be audio webcast simultaneously on our website www.wolterskluwer.com/Investors . A replay facility will be available after the event. About Wolters Kluwer Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world. Wolters Kluwer reported 2012 annual revenues of €3.6 billion. The Group employs over 19,000 people worldwide and maintains operations in over 40 countries across Europe, North America, Asia Pacific and Latin America. The Company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on NYSE Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over- the-counter market in the U.S. (WTKWY). For more information about our products and organization, visit www.wolterskluwer.com , follow @Wolters_Kluwer on Twitter, or search for Wolters Kluwer videos on YouTube. Calendar November 6, 2013           2013 Third-Quarter Scheduled Trading Update February 19, 2014 2013 Full-Year Results Media Investors/Analysts Robert Dekker Meg Geldens Tel. +1 215-521-8928 Tel. + 31 172 641 407 robert.dekker@wolterskluwerhealth.com ir@wolterskluwer.com PDF version of Press Release: http://hugin.info/130682/R/1738444/583155.pdf [HUG#1738444]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Nvidia's Major $500 Million Investment in Wayve for AI Expansion

Updated Category News Views 206

Nvidia Invests $500 Million in Wayve Nvidia, known for its advanced AI technologies, is in discussions to invest a substantial $500 million into the U.K.-based autonomous driving startup Wayve. This move marks a significant step for Nvidia as it seeks to deepen its involvement in the rapidly evolving artificial intelligence sector. Strategic Importance of the Investment...

Continue Reading
Vortex Companies Enhances Leadership with Key Promotions

Updated Category News Views 164

Elevating Leadership at Vortex Companies Vortex Companies, known for its rapid growth in the trenchless infrastructure rehabilitation sector, has recently made significant leadership changes with the promotions of Jonathan Thomas and Connor Mathis. Thomas steps into the role of Senior Regional Vice President for the Coastal Region, while Mathis ascends to Regional Vice...

Continue Reading
Scilex Holding Company Receives FDA Acknowledgment for ELYXYB

Updated Category News Views 118

Scilex Holding Company’s FDA Milestone with ELYXYB Scilex Holding Company, based in Palo Alto, California, has gained significant recognition with the U.S. FDA's acknowledgment of their Supplemental New Drug Application (SNDA) for ELYXYB. This marks a substantial step forward for the company, which is dedicated to creating and advancing non-opioid pain management...

Continue Reading
Bio-Techne Expands AI-Driven Protein Portfolio

Updated Category News Views 8

Advanced Proteins in the Spotlight Bio-Techne’s latest move is creating some serious buzz in the life sciences scene. They're not just talking the talk but walking the walk by expanding their R&D Systems AI-Engineered Designer Protein portfolio. What's the big news? They've engineered heat-stable and hyperactive proteins that promise to shake up fibroblast growth factor...

Continue Reading
PolyPid's D-PLEX100 Trial Results Revolutionize Infection Prevention

Updated Category News Views 146

Groundbreaking Advances in Surgical Infection Prevention PolyPid Ltd. has made headlines recently, unveiling remarkable topline results from their pivotal SHIELD II Phase 3 trial. This innovative study showcased D-PLEX100, a major breakthrough in preventing surgical site infections (SSIs), showing statistically significant reductions in both primary and secondary...

Continue Reading